FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Ann Surg / Seven years’ experience with antilymphoblast globulin ...
Annals of surgery1976; 184(3); 352-368; doi: 10.1097/00000658-197609000-00013

Seven years’ experience with antilymphoblast globulin for renal transplantation from cadaver donors.

Abstract: Antibody of the IgGab type can be isolated from horses immunized with cultured human lymphoblasts plus complete Freund's adjuvant. The essential steps for the production of a safe, potent anti-human lymphoblast globulin (ALG) are: A) the use of early bleedings after immunization to reduce the titer of antibodies which react with red blood cells and platelets; B) careful absorption with human red blood cell stroma and platelets; C) stabilization with non-crystalline silica dioxide; D) chromatography through QAE sephadex to remove pyrogens, microaggregates and possible inhibitors of ALG activity; E) careful safety testing in animals for toxicity and pyrogenicity; and F) testing in vitro for sterility. Such a purified horse ALG (IgGab) can be administered safely intravenously to patients to supplement a standardized immunosuppressive regimen incorporating azathioprine and prednisone. Under these circumstances, allergic reactions are very rare, antibodies to horse IgG do not develop, skin tests to horse IgG remain negative, and immune elimination of circulating horse IgG from the human circulation cannot be demonstrated. The overall results of ALG patient survival and transplant function after 184 consecutive first cadaver transplants at the University of Minnesota demonstrate a statistically significant improvement in both parameters accompanying increases in ALG dose while rigidly utilizing standardized doses of azathioprine and prednisone. There is a significant reduction in the number of grafts lost to rejection; significant reduction in the number of rejection episodes; significant delay in the onset of rejection episodes; but there is no increase in septic loss of patients or kidneys. These efforts could be seen in the gross data or when subgroups controlling for patient age, tissue typing were analyzed. Excluding patients at high risk did not alter the results. The beneficial effects of ALG were particularly striking in good matches. In the highest doses, ALG may be dangerous for older patients with poor matches who develop an increased incidence of septic loss of kidney and/or life. Thus, ALG appears to be a useful adjunct in the early management of cadaver transplants by reducing the incidence and frequency of rejection episodes. The dose should probably be reduced in the older patients who receive kidneys from badly mismatched donors. One cannot conclude from this study that ALG manufactured in other centers by this or other techniques, will accomplish the same results since the multiplicity of factors involved in the success and failure of transplants must be controlled so that the influence of intravening variables in the assessment of ALG effectiveness can be assessed.
Get Full Text
Publication Date: 1976-09-01 PubMed ID: 786192PubMed Central: PMC1344397DOI: 10.1097/00000658-197609000-00013Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper presents an analysis of seven years of experience using anti-human lymphoblast globulin (ALG), a type of antibody, in renal transplantation from cadaver donors. The study found improved patient survival and transplant function rates, with a significant reduction in the rejection of grafts and a delayed onset of rejection episodes. However, high doses of ALG were found to be potentially dangerous for older patients with poorly matched donors.

Methodology of ALG Production

  • The study explains that the antibody used, called antilymphoblast globulin (ALG), is derived from horses immunized with human lymphoblasts and Freund’s adjuvant. This substance assists in stimulating the immune system and increasing the response to vaccination.
  • Safety measures for producing this globulin include using early bleedings after immunization (reducing other antibodies), absorbing it with human red blood cell stroma and platelets, stabilizing it with silica dioxide, and completing chromatography to remove unwanted substances.
  • The prepared ALG is tested for toxicity and pyrogenicity in animals and for sterility in vitro.

Benefits and Risks of ALG in Transplants

  • Once properly prepared and safety-tested, ALG can contribute to a standard immunosuppressive regimen for patients, alongside azathioprine and prednisone, reducing the risk of the patient rejecting the transplant.
  • The study demonstrates that allergic reactions to horse IgG are quite rare and that the immune elimination of circulating horse IgG cannot typically be detected in the human circulation.
  • However, treatment with high doses of ALG can be harmful, particularly for older patients or those with poorly matched donors, as they may suffer from an increased incidence of septic loss of kidney and/or life.

ALG’s Impact on Transplant Success

  • The study, based on the results of 184 first cadaver transplants, displays that the use of ALG along with standardized doses of azathioprine and prednisone notably improves patient survival and transplant function.
  • ALG also resulted in a substantial reduction in the number of graft rejects and rejection episodes and a delay in the onset of rejection
  • These results remained consistent, even when controlling for variables like patient age and tissue typing.
  • The paper concludes by suggesting that the dose of ALG should probably be reduced in older patients or those receiving kidneys from poorly matched donors.

Limitations of the Study

  • The paper ends with a caveat that the results of the study are specific to the ALG produced in their center, and might not be replicable with ALG produced elsewhere or by other methods, due to the various factors that affect transplant success or failure.

Cite This Article

APA
Najarian JS, Simmons RL, Condie RM, Thompson EJ, Fryd DS, Howard RJ, Matas AJ, Sutherland DE, Ferguson RM, Schmidtke JR. (1976). Seven years’ experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg, 184(3), 352-368. https://doi.org/10.1097/00000658-197609000-00013

Publication

Annals of surgery
ISSN: 0003-4932
NlmUniqueID: 0372354
Country: United States
Language: English
Volume: 184
Issue: 3
Pages: 352-368

Researcher Affiliations

Najarian, J S
    Simmons, R L
      Condie, R M
        Thompson, E J
          Fryd, D S
            Howard, R J
              Matas, A J
                Sutherland, D E
                  Ferguson, R M
                    Schmidtke, J R

                      MeSH Terms

                      • Age Factors
                      • Antilymphocyte Serum / adverse effects
                      • Antilymphocyte Serum / isolation & purification
                      • Cadaver
                      • HLA Antigens
                      • Histocompatibility Testing
                      • Humans
                      • Hypersensitivity
                      • Kidney Transplantation
                      • Lymphocytes / analysis
                      • Transplantation, Homologous

                      References

                      This article includes 38 references
                      1. Monaco AP, Codish SD. Survey of the current status of the clinical uses of antilymphocyte serum.. Surg Gynecol Obstet 1976 Mar;142(3):417-26.
                        pubmed: 766248
                      2. Rabellino E, Colon S, Grey HM, Unanue ER. Immunoglobulins on the surface of lymphocytes. I. Distribution and quantitation.. J Exp Med 1971 Jan 1;133(1):156-67.
                        pubmed: 4099713doi: 10.1084/jem.133.1.156google scholar: lookup
                      3. Jondal M, Holm G, Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.. J Exp Med 1972 Aug 1;136(2):207-15.
                        pubmed: 4114496doi: 10.1084/jem.136.2.207google scholar: lookup
                      4. Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.. Int J Cancer 1973 May;11(3):499-520.
                        pubmed: 4133943doi: 10.1002/ijc.2910110302google scholar: lookup
                      5. Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation.. Surg Gynecol Obstet 1967 Feb;124(2):301-8.
                        pubmed: 4163340
                      6. Najarian JS, Simmons RL, Gewurz H, Moberg A, Merkel F, Moore GE. Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man.. Ann Surg 1969 Oct;170(4):617-32.
                        pubmed: 4186508doi: 10.1097/00000658-196910000-00013google scholar: lookup
                      7. Buselmeier TJ, Simmons RL, Najarian JS, Duncan DA, von Hartitzsch B, Kjellstrand CM. The clinical application of a new prosthetic arteriovenous shunt. Characteristics and advantages over the standard A-V shunt and the A-V fistula.. Nephron 1974;12(1):22-8.
                        pubmed: 4209841doi: 10.1159/000180253google scholar: lookup
                      8. Minowada J, Nonoyama M, Moore GE, Rauch AM, Pagano JS. The presence of the Epstein-Barr viral genome in human lymphoblastoid B-cell lines and its absence in a myeloma cell line.. Cancer Res 1974 Aug;34(8):1898-903.
                        pubmed: 4366935
                      9. Turcotte JG, Feduska NJ, Haines RF, Freier DT, Gikas PW, McDonald FD, Johnson AG, Morrell RM, Thompson NW. Antithymocyte globulin in renal transplant krecipients. A clinical trial.. Arch Surg 1973 Apr;106(4):484-8.
                        pubmed: 4572345doi: 10.1001/archsurg.1973.01350160102016google scholar: lookup
                      10. Toledo-Pereyra LH, Condie RM, Malmberg R, Simmons RL, Najarian JS. A fibrinogen-free plasma perfusate for preservation of kidneys for one hundred and twenty hours.. Surg Gynecol Obstet 1974 Jun;138(6):901-5.
                        pubmed: 4597110
                      11. Callender CO, Simmons RL, Yunis EJ, Toledo-Pereyra LH, DeShazo MT, Najarian JS. Anti-HL-A antibodies: Failure to correlate with renal allograft rejection.. Surgery 1974 Oct;76(4):573-80.
                        pubmed: 4606225
                      12. Immons RL, Ozerkis AJ, Hoehn RJ. Antiserum to lymphocytes: interactions with chemical immunosuppressants.. Science 1968 Jun 7;160(3832):1127-30.
                        pubmed: 4869606doi: 10.1126/science.160.3832.1127google scholar: lookup
                      13. Starzl TE, Brettschneider L, Penn I, Schmidt RW, Bell P, Kashiwagi N, Townsend CM, Putnam CW. A trial with heterologous antilymphocyte globulin in man.. Transplant Proc 1969 Mar;1(1):448-54.
                        pubmed: 4944259
                      14. Simmons RL, Moberg AW, Gewurz H, Soll R, Najarian JS. Immunosuppression by antihuman lymphocyte globulin: correlation of human and animal assay systems with clinical results.. Transplant Proc 1971 Mar;3(1):745-8.
                        pubmed: 4999469
                      15. Nagaya H, Sieker HO. Allograft survival: effect of antiserums to thymus glands and lymphocytes.. Science 1965 Nov 26;150(3700):1181-2.
                        pubmed: 5322340doi: 10.1126/science.150.3700.1181google scholar: lookup
                      16. Mitchell RM, Sheil AG, Slafsky SF, Murray JE. The effect of heterologous immune serum on canine renal homografts.. Transplantation 1966 May;4(3):323-9.
                        pubmed: 5335858doi: 10.1097/00007890-196605000-00009google scholar: lookup
                      17. Moberg AW, Gewurz H, Jetzer T, Simmons RL, Najarian JS. Forced flow electrophoretic purification of anti-human antilymphoblast globulin.. Surgery 1970 Nov;68(5):862-9.
                        pubmed: 5528824
                      18. Iwasaki Y, Porter KA, Amend JR, Marchioro TL, Zühlke V, Starzl TE. The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions.. Surg Gynecol Obstet 1967 Jan;124(1):1-24.
                        pubmed: 6016025
                      19. WOODRUFF MF, ANDERSON NF. THE EFFECT OF LYMPHOCYTE DEPLETION BY THORACIC DUCT FISTULA AND ADMINISTRATION OF ANTILYMPHOCYTIC SERUM ON THE SURVIVAL OF SKIN HOMOGRAFTS IN RATS.. Ann N Y Acad Sci 1964 Nov 30;120:119-28.
                        pubmed: 14233856doi: 10.1111/j.1749-6632.1964.tb34710.xgoogle scholar: lookup
                      20. JEEJEEBHOY HF. EFFECTS OF RABBIT ANTI-RAT-LYMPHOCYTE PLASMA ON IMMUNE RESPONSE OF RATS THYMECTOMISED IN ADULT LIFE.. Lancet 1965 Jul 17;2(7403):106-7.
                        pubmed: 14330031doi: 10.1016/s0140-6736(65)92222-1google scholar: lookup
                      21. Monaco AP, Wood ML, Russell PS. Some effects of purified heterologous antihuman lymphocyte serum in man.. Transplantation 1967 Jul;5(4):Suppl:1106-14.
                        pubmed: 4860604doi: 10.1097/00007890-196707001-00046google scholar: lookup
                      22. Simmons RL, Thompson EJ, Kjellstrand CM, Yunis EJ, Condie RM, Mauer SM, Buselmeier TJ, Najarian JS. Parent-to-child and child-to-parent kidney transplants. Experience with 101 transplants at one centre.. Lancet 1976 Feb 14;1(7955):321-4.
                        pubmed: 54736doi: 10.1016/s0140-6736(76)90082-9google scholar: lookup
                      23. Najarian JS, Simmons RL. The clinical use of antilymphocyte globulin.. N Engl J Med 1971 Jul 15;285(3):158-66.
                        pubmed: 4103453doi: 10.1056/NEJM197107152850310google scholar: lookup
                      24. Sheil AG, Kelly GE, Mears D, May J, Johnson JR, Ibels LS, Stewart JH. Antilymphocyte globulin in patients with renal allografts from cadaveric donors. Late results of a controlled trail.. Lancet 1973 Aug 4;2(7823):227-8.
                        pubmed: 4124420doi: 10.1016/s0140-6736(73)93132-2google scholar: lookup
                      25. Inman FP, Nisonoff A. Reversible dissociation of fragment Fc of rabbit gamma-G-immunoglobulin.. J Biol Chem 1966 Jan 25;241(2):322-9.
                        pubmed: 4159369
                      26. Simmons RL, Moberg AW, Gewurz H, Soll R, Tallent MB, Najarian JS. Immunosuppressive assay of antilymphoblast globulin in man: effect of dose, histocompatibility, and serologic response to horse gamma globulin.. Surgery 1970 Jul;68(1):62-8.
                        pubmed: 4193071
                      27. Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA, Gentry S. Association of renal allograft rejection with virus infections.. Am J Med 1974 Mar;56(3):280-9.
                        pubmed: 4360465doi: 10.1016/0002-9343(74)90609-3google scholar: lookup
                      28. Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Renal transplantation in high-risk patients.. Arch Surg 1971 Aug;103(2):290-8.
                        pubmed: 4397867doi: 10.1001/archsurg.1971.01350080206032google scholar: lookup
                      29. Najarian JS, Kjellstrand CM, Simmons RL, Buselmeier TJ, von Hartitzsch B, Goetz FC. Renal transplantation for diabetic glomerulosclerosis.. Ann Surg 1973 Oct;178(4):477-84.
                        pubmed: 4582812doi: 10.1097/00000658-197310000-00010google scholar: lookup
                      30. Condie RM, White JG, Najarian JS. Platelet activity of antilymphocyte serum (ALS) preparations.. Transplant Proc 1973 Mar;5(1):555-9.
                        pubmed: 4735210
                      31. Weil R 3rd, Simmons RL. Combined immunosuppression for canine renal allograft prolongation: antilymphocyte serum plus prednisolone or azathioprine.. Ann Surg 1968 Feb;167(2):239-45.
                        pubmed: 4866845doi: 10.1097/00000658-196802000-00013google scholar: lookup
                      32. Bach JF, Dormont J. Further developments of the rosette inhibition test for the testing of antihuman lymphocyte serum.. Transplantation 1971 Jan;11(1):96-100.
                        pubmed: 4927313doi: 10.1097/00007890-197101000-00016google scholar: lookup
                      33. Halpern B, Cachera JP, Lacombe M, Hathaway A, Crepin Y, Hung BM, Lacassagne JP, Leandri J, Laurent D, Dubost C, de Mendoza M. The efficiency of sheep antidog antilymphocyte serum (SADALS) in the prolongation of canine heart allografts.. Transplant Proc 1969 Mar;1(1):467-9.
                        pubmed: 4944261
                      34. Monaco AP, Abbott WM, Othersen HB, Simmons RL, Wood ML, Flax MH, Russell PS. Antiserum to lymphocytes: prolonged survival of canine renal allografts.. Science 1966 Sep 9;153(3741):1264-7.
                        pubmed: 5331415doi: 10.1126/science.153.3741.1264google scholar: lookup
                      35. Levey RH, Medawar PB. Nature and mode of action of antilymphocytic antiserum.. Proc Natl Acad Sci U S A 1966 Oct;56(4):1130-7.
                        pubmed: 5339289doi: 10.1073/pnas.56.4.1130google scholar: lookup
                      36. Amos DB, Bashir H, Boyle W, MacQueen M, Tiilikainen A. A simple micro cytotoxicity test.. Transplantation 1969 Mar;7(3):220-3.
                        pubmed: 5779102doi: 10.1097/00007890-196903000-00023google scholar: lookup
                      37. WAKSMAN BH, ARBOUYS S, ARNASON BG. The use of specific "lymphocyte" antisera to inhibit hypersensitive reactions of the "delayed" type.. J Exp Med 1961 Dec 1;114(6):997-1022.
                        pubmed: 14004486doi: 10.1084/jem.114.6.997google scholar: lookup
                      38. Monaco AP, Wood ML, Russell PS. Adult Thymectomy: Effect on Recovery from Immunologic Depression in Mice.. Science 1965 Jul 23;149(3682):432-5.
                        pubmed: 17809411doi: 10.1126/science.149.3682.432google scholar: lookup

                      Citations

                      This article has been cited 18 times.
                      1. Masset C, Kerleau C, Blancho G, Hourmant M, Walencik A, Ville S, Kervella D, Cantarovich D, Houzet A, Giral M, Garandeau C, Dantal J. Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients.. Transpl Int 2023;36:10816.
                        doi: 10.3389/ti.2023.10816pubmed: 36819125google scholar: lookup
                      2. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology.. Drugs 2010 Apr 16;70(6):691-732.
                        doi: 10.2165/11315940-000000000-00000pubmed: 20394456google scholar: lookup
                      3. Moudgil A, Puliyanda D. Induction therapy in pediatric renal transplant recipients: an overview.. Paediatr Drugs 2007;9(5):323-41.
                        doi: 10.2165/00148581-200709050-00005pubmed: 17927304google scholar: lookup
                      4. Dharnidharka VR. Post-transplant lymphoproliferative disease: association with induction therapy?. Drugs 2006;66(4):429-38.
                        doi: 10.2165/00003495-200666040-00003pubmed: 16597161google scholar: lookup
                      5. Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. Lessons learned from more than 1,000 pancreas transplants at a single institution.. Ann Surg 2001 Apr;233(4):463-501.
                        doi: 10.1097/00000658-200104000-00003pubmed: 11303130google scholar: lookup
                      6. Matas AJ, Sibley R, Mauer M, Sutherland DE, Simmons RL, Najarian JS. The value of needle renal allograft biopsy. I. A retrospective study of biopsies performed during putative rejection episodes.. Ann Surg 1983 Feb;197(2):226-37.
                        doi: 10.1097/00000658-198302000-00017pubmed: 6297416google scholar: lookup
                      7. Najarian JS, Fryd DS, Strand M, Canafax DM, Ascher NL, Payne WD, Simmons RL, Sutherland DE. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.. Ann Surg 1985 Feb;201(2):142-57.
                        doi: 10.1097/00000658-198502000-00003pubmed: 3882063google scholar: lookup
                      8. Fung JJ, Demetris AJ, Porter KA, Iwatsuki S, Gordon RD, Esquivel CO, Jaffe R, Tzakis A, Shaw BW Jr, Starzl TE. Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.. Nephron 1987;46 Suppl 1(Suppl 1):19-33.
                        doi: 10.1159/000184431pubmed: 3306422google scholar: lookup
                      9. Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF, Dunn DL, Sutherland DE, Najarian JS. Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s.. Ann Surg 1991 Dec;214(6):679-88.
                        doi: 10.1097/00000658-199112000-00007pubmed: 1741647google scholar: lookup
                      10. Bonnefoy-Berard N, Verrier B, Vincent C, Revillard JP. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins.. Immunology 1992 Sep;77(1):61-7.
                        pubmed: 1398765
                      11. Henricsson A, Husberg B, Bergentz SE. The mechanism behind the effect of ALG on platelets in vivo.. Clin Exp Immunol 1977 Sep;29(3):515-22.
                        pubmed: 589869
                      12. Starzl TE, Weil R 3rd, Koep LJ, McCalmon RT Jr, Terasaki PI, Iwaki Y, Schröter GP, Franks JJ, Subryan V, Halgrimson CG. Thoracic duct fistula and renal transplantation.. Ann Surg 1979 Oct;190(4):474-86.
                        doi: 10.1097/00000658-197910000-00007pubmed: 384943google scholar: lookup
                      13. Bakir AA, Dunea G. Current trends in the treatment of uraemia: a view from the United States.. Br Med J 1979 Apr 7;1(6168):914-6.
                        doi: 10.1136/bmj.1.6168.914pubmed: 373854google scholar: lookup
                      14. Ascher NL, Simmons RL, Noreen H, VanHook J, Howard RJ, Sutherland DE, Najarian JS. 100 HLA-identical sibling transplants. Prognostic factors other than histocompatibility.. Ann Surg 1979 Feb;189(2):209-16.
                        doi: 10.1097/00000658-197902000-00013pubmed: 371556google scholar: lookup
                      15. Howard RJ, Condie RM, Sutherland DE, Simmons RL, Najarian JS. The effect of serum ALG concentrations on results following renal transplantation.. Ann Surg 1977 Nov;186(5):619-24.
                        doi: 10.1097/00000658-197711000-00013pubmed: 335988google scholar: lookup
                      16. Matas AJ, Simmons RL, Kjellstrand CM, Najarian JS. Pseudorejection: factors mimicking rejection in renal allograft recipients.. Ann Surg 1977 Jul;186(1):51-9.
                        doi: 10.1097/00000658-197707000-00008pubmed: 327954google scholar: lookup
                      17. Matas AJ, Simmons RL, Kjellstrand CM, Fryd DS, Najarian JS. When should the third renal transplant rejection episode be treated?. Ann Surg 1977 Jul;186(1):104-10.
                        doi: 10.1097/00000658-197707000-00015pubmed: 327950google scholar: lookup
                      18. Weil R, Schröter GP, West JC, Starzl TE. A 14-year experience with kidney transplantation.. World J Surg 1977 Mar;2(1):145-56.
                        doi: 10.1007/BF01665068pubmed: 141173google scholar: lookup
                      Subscribe to our newsletter
                      Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.